GelSana Selected for MedTech Innovator 2025 Cohort
We’re In! GelSana Therapeutics, Inc. Joins the 2025 MedTech Innovator Cohort We’re proud to share that…
News
Read MoreGelSana Selected for MedTech Innovator 2025 Cohort
Melissa Krebs Inducted into the American Institute of Medical and Biological Engineering (AIMBE) College of Fellows
Melissa Krebs, CEO, has been inducted into the American Institute for Medical and Biological Engineering College…
GelSana Awarded Another Phase I SBIR from NIDDK
GelSana is proud to announce that we have been awarded another NIH SBIR Phase I funding…
GelSana Adds Commercialization Expertise with New Board Director, Diana Verrilli
GelSana, an Innosphere Ventures client company, today announced that Diana Verrilli, Chief Growth Officer at DispatchHealth, will join…
GelSana Hires Chief Operating Officer, Jon Fernandez, to Drive Commercialization and Operations Growth
(AURORA, CO) – May 7, 2024 – GelSana, an Innosphere Ventures client company, today announced it has…
GelSana Awarded an AFWERX Phase II SBIR Contract to Develop Novel Polymers for Enhanced Wound Healing in Combat-Related Burn Injuries
(AURORA, CO) – April 10, 2024 – GelSana announces it has been selected by AFWERX for a…
GelSana Wins Inaugural Mines Venture Fund I Investment
(GOLDEN, CO) – February 19, 2024 – GelSana Therapeutics, a Colorado-based biomaterials company founded by Colorado…
GelSana Announces Initial Close on Second Seed Priced Round
Thrilled to announce the initial close on our second Seed fundraising round for GelSana! Innosphere Ventures…
GelSana Selected to Present at Silicon Valley Leaders Forum HealthTech Showcase, November 2023
GelSana was honored to be selected as one of the startups to present at the 2023…